Connect
MJA
MJA

Medication to prevent breast cancer — too much to swallow?

Jerry R Greenfield and Ann I McCormack
Med J Aust 2012; 196 (5): . || doi: 10.5694/mja12.10056
Published online: 19 March 2012

To the Editor: We read with interest the recent article by Harvey and colleagues,1 which eloquently outlines the benefits and risks of selective oestrogen receptor modulators in the prevention of breast cancer in women at moderate-to-high risk.


  • St Vincent’s Hospital, Sydney, NSW.


Correspondence: j.greenfield@garvan.org.au

Competing interests:

No relevant disclosures.

  • 1. Harvey SL, Francis JE, McBride AJ, et al. Medication to prevent breast cancer — too much to swallow? Med J Aust 2011; 195: 646-649. <MJA full text>
  • 2. Monami M, Colombi C, Balzi D, et al. Metformin and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 2011; 34: 129-131.
  • 3. Libby G, Donnelly LA, Donnan PT, et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009; 32: 1620-1625.
  • 4. Pollak M. Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev Res (Phila) 2010; 3: 1060-1065.
  • 5. Shaw LM. The insulin receptor substrate (IRS) proteins: at the intersection of metabolism and cancer. Cell Cycle 2011; 10: 1750-1756.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.